Cerevance reports positive Phase 3 results for Parkinson’s drug solengepras

Cerevance, a Boston biotech spinout from Takeda, announced that its experimental Parkinson’s drug solengepras achieved its primary endpoint in a Phase 3 trial.

The trial enrolled 341 patients with motor fluctuations despite levodopa therapy, randomizing them to placebo, low dose, or high dose of solengepras taken once daily.

Unlike traditional dopamine‑targeting treatments, solengepras inhibits a protein involved in coordination, aiming to reduce “off” time without causing dyskinesia. Participants started with an average of about 5.6 hours of daily off time.

Cerevance said it will meet with the FDA to discuss next steps, including potential regulatory filing. The data suggest the drug could become a new add‑on option for Parkinson’s patients who continue to experience motor fluctuations.